# URGN catalysts: UroGen Pharma Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/urgn/catalysts

> UroGen Pharma Ltd. (URGN) has 3 upcoming catalysts. The next is the UGN-104 primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | UroGen Pharma Ltd. |
| Ticker | URGN (Nasdaq) |
| SEC CIK | 1668243 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/urgn |

## Cash runway

Cash $91.9M as of 2026-09-30; quarterly burn $15.2M; about 18.1 months of runway at that rate (XBRL company facts, accession 0001437749-26-034780).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 15, 2020 | [ZUSDURI (mitomycin) FDA approval](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed, approved | "NDA211728 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20200415, review_priority PRIORITY; sponsor_name UROGEN PHARMA; product JELMYTO (MITOMYCIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211728%22)) |
| Apr 2022 | [Zalifrelimab trial start](https://sec-api.dev/pdufa/zalifrelimab) | URGN |  | completed | "In April 2022, we initiated a multi-arm Phase 1 study, which is expected to support the development of UGN-301 in high-grade NMIBC." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm)) |
| Jan 2024 | [ZUSDURI (mitomycin) NDA/BLA submission](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the CMC sections of the NDA, which we submitted in January 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm)) |
| Apr 2024 | [ZUSDURI (mitomycin) trial start](https://sec-api.dev/pdufa/mitomycin) | URGN | recurrent low-grade intermediate risk NMIBC | completed | "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm)) |
| Apr 2024 | [ZUSDURI (mitomycin) NDA/BLA acceptance](https://sec-api.dev/pdufa/mitomycin) | URGN | recurrent low-grade intermediate risk NMIBC | completed | "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm)) |
| Jun 2024 | [ZUSDURI (mitomycin) PDUFA date](https://sec-api.dev/pdufa/mitomycin) | URGN |  | delayed | "Acceptance Anticipated Results NDA Submission 1 2 Of NDA ODAC PDUFA June 2024 August 2024 October 2024 Q2 2025 June 13, 2025 1." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/d903812dex991.htm)) |
| Aug 2024 | [ZUSDURI (mitomycin) NDA/BLA submission](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "In August 2024, the Company completed the submission of the rolling new drug application ("NDA") for UGN-102." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm)) |
| Oct 2024 | [ZUSDURI (mitomycin) trial start](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "In October 2024, we initiated a Phase 3 study to explore the safety and efficacy of UGN-103 in low-grade, intermediate risk NMIBC." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm)) |
| Oct 2024 | [ZUSDURI (mitomycin) NDA/BLA acceptance](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "While the FDA accepted our NDA for UGN-102 in October 2024 and assigned a PDUFA goal date of June 13, 2025, there is no guarantee that the PDUFA goal date will not be delayed or that the FDA will eventually approve UGN-102 for the indication and patient population that we request or approve the labeling that we believe is necessary or desirable for the successful commercialization of UGN-102, as the FDA does not always meet its PDUFA dates and it has the authority to refuse to approve NDAs for a variety of reasons." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm)) |
| Feb 2025 | [ZUSDURI (mitomycin) trial start](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "In February 2025, the FDA accepted our IND for UGN-104, and we initiated a Phase 3 trial of UGN-104 in low-grade UTUC in June 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm)) |
| March 10, 2025 | [ZUSDURI (mitomycin) earnings report](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/ex_785682.htm)) |
| mid-2025 | [ZUSDURI (mitomycin) trial start](https://sec-api.dev/pdufa/mitomycin) | URGN |  | scheduled | "UroGen plans to initiate a Phase 3 trial to explore the safety and efficacy of UGN-104 by mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm)) |
| May 12, 2025 | [UroGen Pharma Ltd. earnings report](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | completed | "UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm)) |
| May 21, 2025 | [ZUSDURI (mitomycin) FDA advisory committee meeting](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "On the morning of May 21, 2025, the Committee will discuss new drug application (NDA) 215793, for (mitomycin) intravesical solution, submitted by UroGen Pharma, Inc. The proposed indication (use) is for the treatment of adult patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025)) |
| June 12, 2025 | [ZUSDURI (mitomycin) FDA approval](https://sec-api.dev/pdufa/mitomycin) | URGN | with recurrent low-grade intermediate risk NMIBC | completed, approved | "ZUSDURI was approved by the U.S. Food and Drug Administration (FDA) on June 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/ex_925621.htm)) |
| June 13, 2025 | [UroGen Pharma Ltd. PDUFA date](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | scheduled | "The FDA granted a Prescription Drug User Fee Act (PDUFA) target action date of June 13, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm)) |
| June 13, 2025 | [ZUSDURI (mitomycin) PDUFA date](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed, approved | "New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025; assuming approval, commercial launch to immediately follow with product availability in July" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm)) |
| August 7, 2025 | [ZUSDURI (mitomycin) earnings report](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925025242/ex_847591.htm)) |
| September 11, 2025 | [UGN-103 primary completion](https://sec-api.dev/pdufa/ugn-103) | URGN | Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder | completed | "NCT06331299 (A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-11 (ACTUAL); Lead Sponsor UroGen Pharma Ltd.; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06331299)) |
| November 6, 2025 | [ZUSDURI (mitomycin) earnings report](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925033466/ex_880398.htm)) |
| March 2, 2026 | [UroGen Pharma Ltd. earnings report](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | completed | "UroGen Announces ZUSDURITM Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/ex_925621.htm)) |
| May 6, 2026 | [ZUSDURI (mitomycin) earnings report](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/ex_956006.htm)) |
| Q3 2026 | [ZUSDURI (mitomycin) NDA/BLA submission](https://sec-api.dev/pdufa/mitomycin) | URGN |  | scheduled | "UroGen remains on track to submit a New Drug Application (NDA) for UGN-103 in the third quarter of 2026, with potential FDA approval in 2027 and full launch anticipated following receipt of a unique J-Code." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/ex_995856.htm)) |
| Aug 2026 | [ZUSDURI (mitomycin) NDA/BLA acceptance](https://sec-api.dev/pdufa/mitomycin) | URGN | with recurrent low-grade intermediate risk NMIBC supported | completed | "In August 2026, we submitted an NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC supported by the clinical data from the ongoing Phase 3 UTOPIA trial, and in October 2026, we announced the FDA's acceptance of the NDA and the assignment of a Prescription Drug User Fee Act ("PDUFA") target action date of June 14, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm)) |
| August 5, 2026 | [UroGen Pharma Ltd. earnings report](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | completed | "PRINCETON, N.J. Aug 5, 2026-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/ex_995856.htm)) |
| September 28, 2026 | [UGN-103 topline data readout](https://sec-api.dev/pdufa/ugn-103) | URGN | Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder | completed | "NCT06331299 (A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-11 (ACTUAL); Lead Sponsor UroGen Pharma Ltd.; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06331299?tab=results)) |
| Q4 2026 | [UGN-501 trial start](https://sec-api.dev/pdufa/ugn-501) | URGN | recurrent NMIBC in 2026 | scheduled | "UroGen's Investigational New Drug application for UGN-501 has been accepted by the FDA, and the Company plans to initiate its Phase 1 clinical trial in NMIBC in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/ex_995856.htm)) |
| Oct 2026 | [ZUSDURI (mitomycin) NDA/BLA acceptance](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "In October 2026, the FDA accepted for review UroGen's NDA for UGN-103 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm)) |
| Q4 2026 | [ZUSDURI (mitomycin) trial start](https://sec-api.dev/pdufa/mitomycin) | URGN | recurrent, papillary-only high-risk NMIBC | scheduled | "UroGen plans to initiate the Phase 3 LONGVIEW-HR randomized, multicenter trial in the fourth quarter of 2026 evaluating adjuvant UGN-103 versus intravesical gemcitabine in patients with recurrent, papillary-only high-risk NMIBC who previously received Bacillus Calmette-Guérin (BCG) therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm)) |
| November 4, 2026 | [UGN-501 trial start](https://sec-api.dev/pdufa/ugn-501) | URGN |  | completed | "Announced first patient dosed in the UGN-501 Phase 1 trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm)) |
| November 4, 2026 | [UroGen Pharma Ltd. earnings report](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | completed | "PRINCETON, N.J., Nov. 4, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2026, and provided an overview of recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm)) |
| March 2027 | [UGN-104 primary completion](https://sec-api.dev/pdufa/ugn-104) | URGN | Upper Urinary Tract Urothelial Carcinoma; Urothelial Carcinoma | scheduled | "NCT06774131 (A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor UroGen Pharma Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06774131)) |
| Mar to Jun 2027 | [UGN-104 topline data readout](https://sec-api.dev/pdufa/ugn-104) | URGN | Upper Urinary Tract Urothelial Carcinoma; Urothelial Carcinoma | scheduled | "NCT06774131 (A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor UroGen Pharma Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06774131)) |
| June 14, 2027 | [ZUSDURI (mitomycin) PDUFA date](https://sec-api.dev/pdufa/mitomycin) | URGN | with recurrent low-grade intermediate risk NMIBC | scheduled | "The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm)) |

## Drugs

- [ZUSDURI (mitomycin)](https://sec-api.dev/pdufa/mitomycin): with recurrent low-grade intermediate risk nmibc, recurrent low-grade intermediate risk nmibc, with recurrent low-grade intermediate risk nmibc supported, recurrent, papillary-only high-risk nmibc, recurrent lg-ir-nmibc, with recurrent low-grade intermediate risk non-muscle invasive bladder cancer
- [UGN-103](https://sec-api.dev/pdufa/ugn-103): Bladder Cancer
- [UGN-104](https://sec-api.dev/pdufa/ugn-104): Upper Urinary Tract Urothelial Carcinoma
- [UGN-501](https://sec-api.dev/pdufa/ugn-501): recurrent nmibc in 2026, recurrent nmibc, high-grade nmibc in 2026
- [Zalifrelimab](https://sec-api.dev/pdufa/zalifrelimab): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/urgn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "URGN catalysts: UroGen Pharma Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/urgn/catalysts

```bibtex
@misc{secapidev_companies_urgn_catalysts_20261116,
  title        = {URGN catalysts: UroGen Pharma Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/urgn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_urgn_catalysts_20261116","title":"URGN catalysts: UroGen Pharma Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/urgn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
